NVS

Novartis AG

New York Stock Exchange

$83.31

Open: $82.27 High: $83.92 Low: $81.85 Close: $83.274

Range: 2021-09-20 - 2021-09-21

Volume:4,298,244

Market: Open

Get Free API Key

Download as Excel

NVS

Novartis AG Lichtstrasse 35 Basel , 4056 http://www.novartis.com

Novartis AG is a part of the healthcare industry. Its main activity is to research and develop healthcare products and pharmaceuticals such as oncology medicines, generic and biosimilar medicines and eye care devices.

CEO: Joseph Jimenez
Employees: 125,000
Sector: Healthcare
Industry: Drug Manufacturers

Latest Stocks Posts

View All Posts >

NVS News

Latest news about the NVS

Top Research Reports for Facebook, Walmart & Novartis
Today's Research Daily features new research reports on 16 major stocks, including Facebook, Inc. (FB), Walmart Inc. (WMT), and Novartis AG (NVS).
View More →
10 Stocks That Just Received Sell Rating from Analysts
In this article, we discuss the 10 stocks that just received a Sell rating from analysts. If you want to skip our detailed analysis of these stocks, go directly to the 5 Stocks That Just Received Sell Rating from Analysts. The spread of the Delta variant of the coronavirus and the social media amplification of […]
View More →
Novartis Adds Vision Loss Gene Therapy Program Via Arctos Acquisition
Novartis AG (NYSE: NVS) has acquired Arctos Medical, adding a preclinical optogenetics-based AAV gene therapy program and Arctos’ proprietary technology to its ophthalmology portfolio. Deal terms were not disclosed. Related: Why Did Deutsche Bank Downgrade This Big Pharma Stock? Arctos developed its technology as a potential method for treating inherited retinal dystrophies (IRDs) and other diseases that involve photoreceptor loss, such as age-related macular degeneration. Arctos’ proprietary, l
View More →
Novartis buys gene therapy firm Arctos Medical in vision loss treatment push
ZURICH (Reuters) -Swiss drugmaker Novartis said on Tuesday it has bought gene therapy specialist Arctos Medical for an undisclosed amount, aiming to boost its efforts to find treatments for severe vision loss. Arctos's technology is a potential way to treat inherited retinal dystrophies (IRDs) and other diseases that involve photoreceptor loss, such as age-related macular degeneration (AMD). Existing gene therapy treatments aim to correct a specific gene, so only a small number of patients can benefit, Novartis said.
View More →
European Stock Futures Higher; Fed Meeting Looms Large
European stock markets are expected to open higher Tuesday, rebounding from the previous session’s sharp losses, although worries remain about the contagion risks associated with property giant China Evergrande Group, while the Federal Reserve's policy meeting continues to dominate thinking. At 2:05 AM ET (0605 GMT), the DAX futures contract in Germany traded 0.4% higher, CAC 40 futures in France climbed 0.2% and the FTSE 100 futures contract in the U.K. rose 0.5%. European equities sold off heavily on Monday, with the DAX ending 2.3% lower and the CAC 40 down 1.7%, sparked by concerns of a disorderly default in China, potentially hurting China's property and financial sectors at a time when growth in the world's second-largest economy is already slowing.
View More →
Novartis' Kisqali Combo Therapy Extends Survival By One Year In Breast Cancer Patients
Novartis AG (NYSE: NVS) announced results of the final overall survival (OS) analysis of Phase 3 MONALEESA-2 study, which evaluated Kisqali (ribociclib) in combination with letrozole in breast cancer patients. The trial compared the combination therapy to placebo plus letrozole in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer with no prior systemic treatment for advanced disease. The data we
View More →
Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
Novartis today announced results of the final overall survival (OS) analysis of the Phase III MONALEESA-2 study, which evaluated Kisqali® (ribociclib) in combination with letrozole compared to placebo plus letrozole in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer with no prior systemic treatment for advanced disease. These data will be presented as a late-breaker oral presentation at the Eu
View More →
Novartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS)
PROS is a spectrum of rare disorders caused by PIK3CA mutations and is characterized by atypical, visible overgrowths and anomalies in blood vessels, the lymphatic system and other tissuesAt 24 weeks, 38% of patients achieved ≥20% reduction in the volume of the PROS lesions assessed in the primary endpoint analysis; no patients experienced disease progression or death Alpelisib is the first potential treatment to specifically address the root cause of PROS conditionsEPIK-P1 study findings presen
View More →
Novartis' Prostate Cancer Therapy Linked To Improved Quality Of Life
Novartis AG (NYSE: NVS) is building the case for its radioligand therapy, 177Lu-PSMA-617. With positive Phase 3 primary endpoint data in the bag, Novartis at the European Society of Medical Oncology Congress 2021 (ESMO21) presented the therapy's effect on the quality of life and pain. Earlier this year, Novartis revealed that the Phase 3 trial linked 177Lu-PSMA-617 to a four-month median improvement in overall survival. Related Link: Novartis' Prostate Cancer Radioligand Therapy Extended Overall
View More →
Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021
New quality of life data for 177Lu-PSMA-617 plus standard of care shows delay in worsening of health-related quality of life (HRQoL) and pain in heavily pre-treated patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) compared to standard of care alone1 US Food and Drug Administration (FDA) granted Breakthrough Therapy designation to 177Lu-PSMA-617; Submission to FDA and European Medicines Agency on track for 2H21 Novartis committed to reimagining prostate cancer w
View More →
Zymeworks' Zanidatamab Aces Mid-Stage Esophageal Cancer Trial
At the European Society of Medical Oncology Congress 2021 (ESMO21), Zymeworks Inc (NYSE: ZYME) presented encouraging early data on its HER2‑targeted bispecific antibody. Twenty-eight patients were deemed evaluable. Zymeworks’ zanidatamab, combined with one of two chemotherapy regimens, posted an overall response rate of 75% in patients with advanced gastroesophageal adenocarcinoma (GEA) who had not previously received a HER2-targeted cancer therapy. The overall disease control rate (DCR) was 89%
View More →
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View More →
BeiGene's (BGNE) BLA for Tislelizumab in ESCC Accepted by FDA
The FDA accepts for review BeiGene's (BGNE) BLA for tislelizumab to treat patients with locally advanced/metastatic esophageal squamous cell carcinoma after prior systemic therapy.
View More →
Sandoz strengthens pipeline by entering into agreement for biosimilar bevacizumab, a key oncology medicine
Sandoz enters into commercialization agreement for biosimilar bevacizumab with Bio-Thera Solutions, Ltd., for treatment of multiple types of cancers1,2Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access, while contributing to sustainability of healthcare systems Basel, September 8, 2021 — Sandoz, a Novartis division, today announced that it has entered into a commercialization agreement with Bio-Thera Solutions, Ltd. for biosi
View More →
Why Did Wedbush Downgrade Xoma?
Wedbush has cut XOMA Corporation (NASDAQ: XOMA) to neutral from outperform and lowered its price target to $22 from $41. Analyst Liana Moussatos notes that Novartis AG (NYSE: NVS) abandoned iscalimab as a kidney transplant candidate following disappointing phase 2b results. Related Content: Novartis Stops Iscalimab Trial In Kidney Transplant Patients. Novartis continues to assess iscalimab in liver transplantation in the Phase 2b CONTRAIL I study, and in Phase 2a study for Hidradenitis suppurati
View More →
Novartis, NHS England Ink Access Deal For Cholesterol Drug Leqvio
The U.K. government, NHS England, and Novartis AG (NYSE: NVS) unveiled a "world-first" reimbursement deal for providing broader access to anti-cholesterol drug Leqvio (inclisiran) after the U.K.'s healthcare cost agency NICE approved the medicine. The news follows the January 2020 announcement of the deal parameters. The partners are now ready to move into the "implementation phase." After reviewing clinical data from three Phase 3 trials, England's NICE endorsed the drug in patients with a hist
View More →
Novartis signs deal with Britain's NHS for new cholesterol drug Leqvio
Novartis AG said on Wednesday it had agreed a deal with Britain's healthcare service provider for use of the drugmaker's new anti-cholesterol drug Leqvio, after the country's healthcare cost agency NICE approved the medicine. The agreement, whose value was not disclosed, will help with wide access to the Swiss drugmaker's medicine through Britain's National Health Service (NHS) for people at risk of heart disease and for whom conventional treatment has not worked.
View More →
World-first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio® ▼(inclisiran)
Agreement follows positive NICE recommendation and commits to deliver Leqvio® (inclisiran) access via a population health management approach identifying eligible patients across England1 Over three years ~300,000 patients at high risk of a second cardiovascular event are expected to be treated with inclisiran, a small interfering RNA therapy administered as a 6-monthly maintenance dose‡, in the community settingLong-term elevated LDL cholesterol (LDL-C) is a known cause of atherosclerotic cardi
View More →
Novartis presents important overall survival and quality-of-life results across solid tumor portfolio, among other key data at ESMO
New Kisqali® (ribociclib)* overall survival (OS) results from MONALEESA-2 trial in HR+/HER2− advanced breast cancer patients in the first-line settingHealth-related quality of life, pain and safety outcomes from phase III VISION trial of investigational radioligand therapy 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancerData supporting upcoming regulatory filings for tislelizumab in people with squamous and non-squamous non-small cell lung cancer (NSCLC), and for a
View More →
UCB Gets EU Approval For Bimekizumab In Psoriasis
The European Commission has cleared UCB's (OTC: UCBJF) Bimzelx (bimekizumab) for moderate to severe plaque psoriasis in adults. UCB's confidence lies in head-to-head studies that pitted Bimzelx against Novartis AG's (NYSE: NVS) Cosentyx (secukinumab) and found that it was better at achieving complete clearance of skin lesions at both 16 and 48 weeks. Bimekizumab is approved at a recommended dose of 320 mg, administered by two subcutaneous injections every four weeks to week 16 and every eight we
View More →

NVS

NVS

Novartis AG Lichtstrasse 35 Basel , 4056 http://www.novartis.com

Latest Stocks Posts

View All Posts >

NVS News

Latest news about the NVS

Request a consultation.

The Top Decentralized Oracles in 2021

How Does the Stock Market Work?

How to become a good Quant Trader

NVS

NVS

Novartis AG Lichtstrasse 35 Basel , 4056 http://www.novartis.com

Share NVS Stock Page

Latest Stocks Posts

View All Posts >

NVS News

Latest news about the NVS

The Top Decentralized Oracles in 2021

How Does the Stock Market Work?

How to become a good Quant Trader